JP Morgan Chase
AEGR

JP Morgan Chase’s Aegerion Pharmaceuticals AEGR Stock Holding History

JP Morgan Chase’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-140,680
Closed -$520K – 5149
2016
Q1 		$520K Buy
140,680
+7,826
+6% +$48.5K ﹤0.01% 3326
2015
Q4 		$1.34M Buy
+132,854
New +$1.6M ﹤0.01% 2973
2015
Q2 		– Sell
-459,853
Closed -$12M – 4313
2015
Q1 		$12M Buy
459,853
+89,642
+24% +$2.28M ﹤0.01% 1784
2014
Q4 		$7.75M Sell
370,211
-1,394,854
-79% -$35.1M ﹤0.01% 2116
2014
Q3 		$58.9M Sell
1,765,065
-175,556
-9% -$5.45M 0.01% 817
2014
Q2 		$62.3M Sell
1,940,621
-525,302
-21% -$19.6M 0.02% 750
2014
Q1 		$114M Buy
2,465,923
+650,966
+36% +$38.2M 0.03% 510
2013
Q4 		$129M Buy
1,814,957
+143,824
+9% +$11M 0.04% 452
2013
Q3 		$143M Buy
1,671,133
+37,368
+2% +$3.17M 0.04% 431
2013
Q2 		$103M Buy
+1,633,765
New +$86.7M 0.03% 496

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase's AEGR Position: Q2 2016 in Review

JP Morgan Chase sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 140,680 shares — an estimated $520K sold.

JP Morgan Chase first reported a position in AEGR in Q2 2013 and held it in 10 quarters. The position peaked at $143M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • JP Morgan Chase reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • JP Morgan Chase sold 140,680 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $520K.
  • JP Morgan Chase first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • JP Morgan Chase's Aegerion Pharmaceuticals position peaked at $143M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on JP Morgan Chase's 13F filing for Q2 2016, filed 8 Aug 2016.